PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Oxygen0 citationsOpen Access

HIF-1α Signaling in Uterine Fibroids: A Central Integrator of Hypoxic, Hormonal, and Fibrotic Pathways

View Full Paper
STSruthi TatavarthiVVValentina VanosACAbigail Combs

Key Points

  • The review aims to delineate the molecular regulation of HIF-1α and its role in uterine fibroid biology.
  • Synthesized literature on HIF-1α regulation in uterine fibroids
  • Discussed crosstalk with steroid hormones and inflammatory pathways
  • Evaluated therapeutic strategies targeting HIF-1α
  • HIF-1α drives angiogenesis and extracellular matrix remodeling in fibroids.
  • Interacts with estrogen and progesterone signaling pathways.
  • Involved in TGF-β/SMAD-driven fibrosis and NF-κB-mediated inflammation.

Abstract

Uterine fibroids (leiomyomas) are common benign smooth muscle tumors that impose substantial symptom burden and healthcare costs worldwide. Although uterine fibroid (leiomyoma) pathogenesis is multifactorial, hypoxia has emerged as a key feature of the uterine fibroid (leiomyoma) microenvironment, particularly within poorly perfused tumor cores. Hypoxia-inducible factor-1α (HIF-1α) is a central transcriptional regulator of cellular adaptation to low oxygen and coordinates downstream programs that support angiogenesis, metabolic reprogramming, cell survival, and extracellular matrix (ECM) remodeling. In uterine fibroids (leiomyomas), these HIF-1α–dependent processes intersect with steroid hormone signaling, growth factor pathways, inflammatory mediators, and redox imbalance, together promoting tumor persistence and progressive fibrosis. This review synthesizes the molecular regulation of HIF-1α, highlights major HIF-linked effector pathways relevant to uterine fibroid (leiomyoma) biology, and emphasizes mechanistic crosstalk with estrogen- and progesterone-responsive signaling, TGF-β/SMAD-driven fibrosis, NF-κB-mediated inflammation, and metabolic checkpoint pathways including mTOR and AMPK. Finally, we evaluate emerging therapeutic strategies that target HIF-1α directly or indirectly through upstream regulators.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tatavarthi et al. (2026) studied this question.

synapsesocial.com/papers/69e4734c010ef96374d8f1c2https://doi.org/10.3390/oxygen6020009
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities2024 · 3 citations
  2. 2HORMONAL AND METABOLIC FACTORS IN THE DEVELOPMENT OF UTERINE FIBROIDS2026
  3. 3The epidemiology and pathogenesis of uterine fibroids2025
  4. 4The Role of STAT-3 and IL-26 Signaling Pathways in Leiomyoma Pathophysiology2025
  5. 5The Potential of Transforming Growth Factor-Beta1 (TGFβ1) in Fibrotic Tissue of Leiomyoma Specimens2024